IN2015DN02577A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02577A IN2015DN02577A IN2577DEN2015A IN2015DN02577A IN 2015DN02577 A IN2015DN02577 A IN 2015DN02577A IN 2577DEN2015 A IN2577DEN2015 A IN 2577DEN2015A IN 2015DN02577 A IN2015DN02577 A IN 2015DN02577A
- Authority
- IN
- India
- Prior art keywords
- conjugates
- specific
- maytansines
- peptide
- processes
- Prior art date
Links
- 239000000562 conjugate Substances 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Specific conjugates containing maytansines and a binding protein or peptide , and processes for making them , are described. The conjugates use specific linker technology which gives advantages over known antibody -drug conjugates.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261717743P | 2012-10-24 | 2012-10-24 | |
PCT/GB2013/052662 WO2014064424A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN02577A true IN2015DN02577A (en) | 2015-09-11 |
Family
ID=49488609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2577DEN2015 IN2015DN02577A (en) | 2012-10-24 | 2013-10-11 |
Country Status (20)
Country | Link |
---|---|
US (1) | US20150283259A1 (en) |
EP (1) | EP2911696B1 (en) |
JP (1) | JP6328649B2 (en) |
KR (1) | KR20150085808A (en) |
CN (1) | CN104755106B (en) |
AU (1) | AU2013336410B2 (en) |
BR (1) | BR112015008311A2 (en) |
CA (1) | CA2884359A1 (en) |
DK (1) | DK2911696T3 (en) |
ES (1) | ES2652513T3 (en) |
HK (1) | HK1208186A1 (en) |
HU (1) | HUE037604T2 (en) |
IL (1) | IL237673A0 (en) |
IN (1) | IN2015DN02577A (en) |
MX (1) | MX2015005124A (en) |
NO (1) | NO2789793T3 (en) |
RU (1) | RU2015119557A (en) |
SG (1) | SG11201501955VA (en) |
WO (1) | WO2014064424A1 (en) |
ZA (1) | ZA201501996B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY183572A (en) | 2013-03-15 | 2021-02-26 | Regeneron Pharma | Biologically active molecules, conjugates thereof, and therapeutic uses |
WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
WO2015031396A1 (en) | 2013-08-26 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
EP3145552B1 (en) * | 2014-05-23 | 2020-03-04 | Novartis AG | Methods for making conjugates from disulfide-containing proteins |
US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
KR20170071485A (en) | 2014-10-14 | 2017-06-23 | 폴리테릭스 리미티드 | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
GB2531715A (en) * | 2014-10-24 | 2016-05-04 | Polytherics Ltd | Novel drug conjugates |
EP3220956B1 (en) * | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
EP3331569A1 (en) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
US9950076B2 (en) | 2016-01-25 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
WO2017178828A1 (en) | 2016-04-14 | 2017-10-19 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
WO2017212250A1 (en) | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
GB201615725D0 (en) * | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
WO2018086139A1 (en) | 2016-11-14 | 2018-05-17 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
AU2019452577B2 (en) | 2019-06-29 | 2023-08-24 | Hangzhou Dac Biotech Co., Ltd. | Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
WO2022051591A2 (en) | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
CA3213295A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
CN117147824A (en) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | Antibody conjugate and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
SG195524A1 (en) * | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2007038658A2 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
PT2211904T (en) * | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Cd19 binding agents and uses thereof |
CN102083461B (en) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | Potent conjugates and hydrophilic linkers |
US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
UY32913A (en) * | 2009-10-02 | 2011-04-29 | Sanofi Aventis | NEW MAITANSINOIDS AND THE USE OF SUCH MAITANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY |
CA2876365A1 (en) * | 2012-06-19 | 2013-12-27 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
-
2012
- 2012-04-24 NO NO14172620A patent/NO2789793T3/no unknown
-
2013
- 2013-10-11 SG SG11201501955VA patent/SG11201501955VA/en unknown
- 2013-10-11 RU RU2015119557A patent/RU2015119557A/en not_active Application Discontinuation
- 2013-10-11 WO PCT/GB2013/052662 patent/WO2014064424A1/en active Application Filing
- 2013-10-11 CA CA2884359A patent/CA2884359A1/en not_active Abandoned
- 2013-10-11 HU HUE13783360A patent/HUE037604T2/en unknown
- 2013-10-11 DK DK13783360.4T patent/DK2911696T3/en active
- 2013-10-11 KR KR1020157009803A patent/KR20150085808A/en not_active Application Discontinuation
- 2013-10-11 US US14/437,571 patent/US20150283259A1/en not_active Abandoned
- 2013-10-11 CN CN201380055945.7A patent/CN104755106B/en active Active
- 2013-10-11 AU AU2013336410A patent/AU2013336410B2/en active Active
- 2013-10-11 EP EP13783360.4A patent/EP2911696B1/en active Active
- 2013-10-11 MX MX2015005124A patent/MX2015005124A/en unknown
- 2013-10-11 BR BR112015008311A patent/BR112015008311A2/en not_active Application Discontinuation
- 2013-10-11 ES ES13783360.4T patent/ES2652513T3/en active Active
- 2013-10-11 IN IN2577DEN2015 patent/IN2015DN02577A/en unknown
- 2013-10-11 JP JP2015538561A patent/JP6328649B2/en active Active
-
2015
- 2015-03-11 IL IL237673A patent/IL237673A0/en unknown
- 2015-03-23 ZA ZA2015/01996A patent/ZA201501996B/en unknown
- 2015-09-11 HK HK15108931.8A patent/HK1208186A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2013336410B2 (en) | 2017-08-03 |
BR112015008311A2 (en) | 2017-07-04 |
JP2015536329A (en) | 2015-12-21 |
ES2652513T3 (en) | 2018-02-02 |
US20150283259A1 (en) | 2015-10-08 |
JP6328649B2 (en) | 2018-05-23 |
MX2015005124A (en) | 2015-10-29 |
IL237673A0 (en) | 2015-04-30 |
HUE037604T2 (en) | 2018-09-28 |
SG11201501955VA (en) | 2015-04-29 |
DK2911696T3 (en) | 2018-01-08 |
NO2789793T3 (en) | 2018-01-27 |
CN104755106A (en) | 2015-07-01 |
CN104755106B (en) | 2018-03-13 |
HK1208186A1 (en) | 2016-02-26 |
WO2014064424A1 (en) | 2014-05-01 |
KR20150085808A (en) | 2015-07-24 |
CA2884359A1 (en) | 2014-05-01 |
EP2911696A1 (en) | 2015-09-02 |
RU2015119557A (en) | 2016-12-20 |
AU2013336410A1 (en) | 2015-04-09 |
EP2911696B1 (en) | 2017-09-20 |
ZA201501996B (en) | 2016-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN02577A (en) | ||
NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
MX2019012201A (en) | Self-stabilizing linker conjugates. | |
MY169147A (en) | Drug-protein conjugates | |
EA201992456A2 (en) | SELF-STABILIZING LINKER CONJUGATES | |
WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
MX2019003214A (en) | Stable dual variable domain immunoglobulin protein formulations. | |
GEP20227398B (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof | |
EP2873678A4 (en) | Cell-penetrating peptide, conjugate comprising same and composition comprising same | |
EP3538080A4 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
EP3082797A4 (en) | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | |
NZ737471A (en) | Hydrophilic linkers for conjugation | |
MX2017011281A (en) | Amatoxin-antibody conjugates. | |
MX342860B (en) | Antibody-drug conjugates. | |
WO2015151080A3 (en) | Specific conjugation of cell-binding molecules | |
EP4276200A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
MX366813B (en) | Cd3 binding polypeptides. | |
PH12018500046A1 (en) | Anti-mesothelin antibodies and immunoconjugates | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
WO2011142858A3 (en) | Chlorotoxin variants, conjugates, and methods for their use | |
MX2013007371A (en) | Radiolabled her2 binding peptides. | |
EP2885321A4 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
EP3013789A4 (en) | Amino acid and peptide conjugates and conjugation process | |
IL272931A (en) | Peptide conjugates, conjugation process, and uses thereof |